According to a Chicago Bridge & Iron (NYSE: CBI)
presentation, the LNG project capital expenditures over the next two
years will reach over $70 billion. The spending will reach a plateau in
2015 at over $45 billion and max out around $50 billion in 2017. Not bad
for a market that topped out around $30 billion in 2012 and plunged
this year.
Probably not surprising, but a main beneficiary will be more »
Disclosure: No positions mentioned. Please review the disclaimer page for more info.
After the close, Rite Aid (RAD) announced the intent to vote on a reverse split at a special meeting on March 21. The stock trades below $1 and the company needs to regain compliance with the NYSE so the move isn't surprising.
Snap (SNAP)reports better than expected numbers, but the numbers are still very weak. The stock won't hold this rally. Q4 Non-GAAP EPS of -$0.04 beats by $0.03.Revenue of $389.82M (+36.4% Y/Y) beats by $12.83M.DAUs - 186M vs 184M.
The key number is that Snap is still losing money and the guidance for Q1 is rather weak. The social messaging service had negative FCF of $149 million and a similar net loss of $158 million.
When a company is losing a sizable amount, the stock won't hold gains based on beating estimates. Snap has to show a more legitimate path to profits, than the CEO saying it while the CFOs keep leaving. Another adjusted EBITDA loss in Q1 of $150 million is another ugly start to another year.
Q1 2019 Outlook - Revenue is expected to be between $285 million and $310 million, or grow between 24% and 34% compared to Q1 2018.- Adjusted EBITDA is expected to be between $(165) million and $(140) million, compared to $(218) million in Q1 2018.
Do not chase Snap on th…
Investing in a biotech goes far beyond whether or not the company can get key drugs approved. How the company finances the cash burning trials is very crucial to long-term valuation and that is where Novavax (NVAX) is crushing shareholders.
Comments